Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 15, 2004; 10(2): 186-189
Published online Jan 15, 2004. doi: 10.3748/wjg.v10.i2.186
Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP producing hepatocarcinoma cell
Yu-Jun Shi, Jian-Ping Gong, Chang-An Liu, Xu-Hong Li, Ying Mei, Can Mi, Yan-Ying Huo
Yu-Jun Shi, Jian-Ping Gong, Chang-An Liu, Xu-Hong Li, Ying Mei, Department of General Surgery, the Second College of Clinical Medicine and the Second Affiliated Hospital of Chongqing University of Medical Sciences, Chongqing 400010, China
Can Mi, Department of Pathology, Basic Medical College, Chongqing University of Medical Sciences, Chongqing 400016, China Yan-Ying Huo, Institute for Radiology, Military Academy of Medical Sciences, Beijing 100850, China
Author contributions: All authors contributed equally to the work.
Supported by the Key Program of Medical Science Foundation of Chongqing Public Health Bureau, [2001] 01-1-018
Correspondence to: Professor Chang-An Liu, Department of General Surgery, the Second College of Clinical Medicine and the Second Affiliated Hospital of Chongqing University of Medical Science, Chongqing 400010, China. shiyujun1128@hotmail.com
Telephone: +86-23-63848842
Received: August 11, 2003
Revised: October 16, 2003
Accepted: October 23, 2003
Published online: January 15, 2004

Abstract

AIM: To construct a recombinant adenoviral vector carrying AFP promoter and EGFP gene for specific expression of EGFP gene in AFP producing hepatocellular carcinoma (HCC) HepG2 cells.

METHODS: Based on the Adeno-XTM expression system, the human immediate early cytomegalovirus promoter (PCMV IE) was removed from the plasmid, pshuttle, and replaced by a 0.3 kb α-fetoprotein (AFP) promoter that was synthesized by polymerase chain reaction (PCR). The enhanced green fluorescent protein (EGFP) gene was inserted into the multi-clone site (MCS), and then the recombinant adenovirus vector carrying the 0.3 kb AFP promoter and EGFP gene was constructed. Cells of a normal liver cell line (LO2), a hepatocarcinoma cell line (HepG2) and a cervical cancer cell line (HeLa) were transfected with the adenovirus. Northern blot and fluorescence microscopy were used to detect the expression of the EGFP gene at mRNA or protein level in three different cell lines.

RESULTS: The 0.3 kb AFP promoter was synthesized through PCR from the human genome. The AFP promoter and EGFP gene were directly inserted into the plasmid pshuttle as confirmed by restriction digestion and DNA sequencing. Northern blot showed that EGFP gene was markedly transcribed in HepG2 cells, but only slightly in LO2 and HeLa cells. In addition, strong green fluorescence was observed in HepG2 cells under a fluorescence microscopy, but fluorescence was very weak LO2 and HeLa cells.

CONCLUSION: Under control of the 0.3 kb human AFP promoter, the recombinant adenovirus vector carrying EGFP gene can be specially expressed in AFP-producing HepG2 cells. Therefore, this adenovirus system can be used as a novel, potent and specific tool for gene-targeting therapy for the AFP positive primary hepatocellular carcinoma.




INTRODUCTION

In recent years, research in tumor gene therapy has made great progress in laboratory, However, there is an urgent need for gene therapy in clinical practice. Recombinant adenovirus is one of the most popular and promising tools for gene therapy[1,2]. But how to construct a proper recombinant adenovirus vector carrying the interested gene that is specifically expressed only in target tumor cells has become the bottle neck which restricts the application of the vector in clinical gene therapy for tumors[3,4]. The aim of this study was to construct a recombinant adenovirus vector carrying a 0.3 kb AFP promoter, and to investigate the expression of enhanced green fluorescent protein (EGFP) gene that was inserted into the vector in AFP positive hepatocarcinoma cells.

MATERIALS AND METHODS
Reagents

EX Taq DNA polymerase, T4 ligase, DNA isolation and purification kit were purchased from Promega (USA), restriction endonucleases and the DNA marker from Takara Biotechnology, Dalian (China), LipofectaminTM 2000 from Invitrogen (USA), and RPMI 1640 medium and fetal calf serum from Hyclone (USA).

Cell lines

Hepatocarcinoma cell line, HepG2, was a gift from Professor Wei-Xue Tang, Department of Pathophysiology, Chongqing University of Medical Sciences. A normal hepatocyte cell line, LO2, and human cervical cancer cell line, HeLa, were preserved in our laboratory. Low-passage HEK 293 cells were obtained from the Institute for Cytobiology, Chinese Academy of Sciences, Shanghai. All cells were cultured in RPMI-1640 medium containing 10% fetal calf serum at 37 °C in saturated humidified air with 5% CO2. The cells were subcultured once every three days.

Vectors

Adenovirus vector Adeno-XTM expression system and pEGFP-C1 were purchased from Clontech Corporation (USA).

Polymerase chain reaction (PCR)

PCR was employed to amplify human AFP promoter and EGFP gene from HepG2 cell genomic DNA and pEGFP-C1, respectively. Specific primers for AFP promoter were as follows: 5’-GCG CTA GCA TTC TGT AGT TTG AGG AG-3’ (sense), 5’-ATG GGC CCA TTG GCA GTG GTG GAA-3’ (antisense). NheI and ApaI sites were introduced into the sense and antisense primer, respectively, as underlined. Specific primers for EGFP gene were as follows: 5’-AAG GGC CCT TTA GTG AAC CGT CAG AT-3’ (sense), 5’-GCC TTA AGT TAT CTA GAT CCG GTG GAT-3’ (antisense). ApaI and AflII sites were introduced into the sense and antisense primer, respectively.To remove the pCMV IE from the pshuttle, PCR was used to amplify the 99-744 region of pshuttle, and specific primers were as follows: 5’-AGC CAG TAT CTG CTC CCT GCT TGT G-3’ (sense), 5’-ATG CTA GCG GTG CCA AAA CAA ACT CCC A-3’ (antisense). NheI site was introduced into the antisense primer.

PCR was performed in a total volume of 50 µl consisting of 1 µM each primer, 200 µM each dNTP, 5 µl 10×polymerase reaction buffer, 1.25U EX taq DNA polymerase and 1 µl DNA template. The samples were heated to 94 °C for 5 min followed by amplification for 30 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 50 s. After the last cycle, a final extension step was at 72 °C for 7 min. Then 5 µl of each product was analyzed by 1% agarose gel (containing 0.5 µg/ml EB) electrophoresis. PCR products were purified from the agarose gel using DNA purification kit.

Construction of the adenoviral vector

pshuttle and the PCR products of 99-744 region were both doubly digested with MluI and NheI, and the digested products were ligated with T4 ligase. MluI site was 256, and the NheI was 921 in pshuttle. The 256-921 region of the pshuttle was removed from the plasmid, and replaced by the region of 256-744, then the 744-921 region containing the pCMV IE was removed from pshuttle. Thus, a new plasmid pCMV(-) was constructed.

Subsequently, the pCMV(-) and AFP PCR products were doubly digested with NheI and ApaI. The 0.3 kb AFP promoter was inserted into the pCMV(-), which was called pAFP. Then the pCMV IE was replaced by the AFP promoter.

To insert the EGFP gene into the pAFP, both the pAFP and EGFP PCR products were doubly digested with ApaI and AflII. The digested products were Ligated to construct pAFP-EGFP.

The newly constructed plasmid pAFP-EGFP was then doubly digested with PI-Sce/I-Ceu I (New England Biolabs. UK), and the purified product was ligated with Adeno-X genome DNA. It was amplified in E.coli DH5α. The HEK293 cells were transfected with recombinant adenovirus which was linearized with PacI, as described in the manual. In brief, the HEK293 cells were cultured in a 60 mm plate, and 10 µl Pac I-digested Adeno-X DNA was added in the culture medium when the cells were 50%-70% confluent, then the cells were transfected with Lipofectamin and incubated for another week. For virus collection, the cells were lysed with three consecutive freeze-thaw cycles, and the virus was collected from supernatant. The titer of the virus was about 1×107 pfu/ml, which was determined with end-point dilution assay.

Northern blot analysis

HepG2, LO2 and HeLa cells were cultured in 6-well plates, and the medium was removed after 24 h, followed by addition of adenovirus at multiplicity of infection (M.O.I) of 100 plaque-forming units (pfu)/cell, and fresh culture medium was added 4 h later. After 48 h of normal culture, total RNA was extracted from the cells for Northern blot. In brief, 10 µg total RNA of each sample was added to 10 g·L-1 formaldehyde denatured agarose gel, and electrophoresis was performed. mRNA was transferred onto the nitrocellular (NC) membranes by capillary blot, and exposed to 254 nm ultraviolet for 1 min (600×100 µJ·cm-1) to fix mRNA. The NC membranes were pre-hybridized for 3 h at 42 °C. The cDNA probes were labeled by a random primer method. The probes were added and hybridized at 42 °C for 20 h. Then the membranes were washed, dried and used for X-ray film autoradiography at -70 °C in a black box for 48 h. The relative amount of EGFP cDNA was semi-quantified from relative optical density of the band, using a Bio-image analysis system (Bio-Rad Doc Gel 2000, USA).

Fluorescence microscopy

The cells were cultured and transfected with the recombinant adenovirus as described above. Fluorescent images were captured at 490 nm using a Nikon Eclipse E1000 microscope.

RESULTS
PCR amplification and DNA sequencing of AFP promoter

Electrophoretic results of PCR product of the human 0.3 kb AFP promoter are shown in Figure 1. The sequence of the promoter was described as below:

Math 1

Math 1
Math 1 Math(A1).
Figure 1
Figure 1 Human 0. 3 kb AFP promoter.
Enzyme digestion analysis of the recombinant pshuttle

The plasmid pshuttle and the 99-744 region of the PCR product were both doubly digested with MluI and NheI (Figure 2). A 670 bp fragment was released from pshuttle, and replaced by a 490 bp fragment that was digested from the PCR product. The pCMV IE was removed from the pshuttle.

Figure 2
Figure 2 Plasmid pshuttle and PCR product doubly-digested with MluI/NheI. M: marker, 1: the PCR product of 99-744 re-gion of pshuttle, 2: the product of PCR doubly digested with MluI/NheI, 3: pshuttle, 4: doubly-digested pshuttle with MluI/ NheI, a 670 bp fragment was released from pshuttle.
Specific expression of EGFP gene in HepG2 cells

As shown in Figure 3, strong expression of EGFP mRNA was observed in HepG2 cells but was weak in AFP negative LO2 and HeLa cells, only 38% and 17% of that in HepG2 cells, respectively.

Figure 3
Figure 3 A: Transcription levels of EGFP shown by Northern blot in three different cell lines, B: Transcription levels of EGFP gene detected by semi-quantity analysis in three cell lines. Lane 1, HeLa cell; lane 2, HepG2 cell; lane 3, LO2 cell.

Under fluorescence microscopy, green fluorescence indicating expression of EGFP was strong in HepG2 cells (Figure 4A) but very weak in LO2 (Figure 4B) and invisible in HeLa cells.

Figure 4
Figure 4 Expression of EGFP mRNA in HepG2 cells (A) and LO2 cells (B) ×200.
DISCUSSION

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. All the treatment strategies used today had a poor outcome[5-7]. Gene therapy might be a promising way[8,9]. Gene transfer into specific tissues or cell types is a key technique in the development of gene therapy. A tissue-specific promoter has been found to be potentially valuable for the study of specific gene function and for gene therapy[10-14], as it permited a linked cytotoxic or any other gene to be expressed specifically in target cells[15-17]. The AFP could be re-expressed in the majority of hepatocellular carcinomas[18,19], and thus utility of the AFP promoter for gene therapy against HCC might be a rational approach[20-22].

Adenoviral gene transfer is one of the most reliable methods for introducing genes into almost all types of mammalian cells and for expressing the genes at high levels since many cells receive multiple copies of the recombinant genome. Gene therapy using replication-competent adenovirus that selectively propagates in tumor cells might be an effective treatment for cancer[23,24]. We developed an adenovirus carrying an AFP promoter, thus the replication of the target gene was restricted specifically in AFP-producing HCC[25]. The full length AFP promoter was 5.1 kb[26,27], previous studies have shown that the 0.3 kb of the AFP promoter had an enough activity to stimulate AFP transcription containing a glucocorticoid response element and two binding sites of hepatocyte nuclear factor (HNF)-1, a hepatocyte-specific transcriptional factor, and a TATA box, but no typical CCAAT sequence[28,29].

In this study, primers containing specific enzyme-cutting sites were designed to amplify the 0.3 kb AFP promoter from human genome, and the 0.3 kb sequence was cloned into the plasmid pshuttle to replace the primary CMV promoter. EGFP gene as a target gene was inserted into the downstream of AFP promoter. Then AFP expressing hepatocarcinoma cells (HepG2), AFP negative normal hepatocytes (LO2) and HeLa cells were transfected with the recombinant adenovirus. Northern blot showed that EGFP gene was dramatically transcribed in HepG2 cells, however, in LO2 and HeLa cells, the transcription was very weak. Under fluorescent microscopy, green fluorescence was strong in HepG2 cells, but very weak in the other two cell lines. Therefore, this recombinant adenovirus carrying the 0.3 kb AFP promoter can be used as a proper vector to express the interested gene in AFP expressing hepatocarcinoma cells or tissues.

It has been reported that the promoter activity of 0.3 kb AFP promoter was limited for transcription of downstream genes[30,31]. For this reason, several enhancers have been inserted into the upstream of the promoter in order to upgrade its activity[32-35]. In our study, the original enhancer in pshuttle was reserved, which might contribute to the satisfactory transcription of the downstream gene using the 0.3 kb promoter.

Footnotes

Edited by Xia HHX and Wang XL

References
1.  Alemany R, Lai S, Lou YC, Jan HY, Fang X, Zhang WW. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 1999;6:21-25.  [PubMed]  [DOI]
2.  Kanai F. Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector. Mol Biotechnol. 2001;18:243-250.  [PubMed]  [DOI]
3.  Murayama Y, Tadakuma T, Kunitomi M, Kumai K, Tsutsui K, Yasuda T, Kitajima M. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene. J Surg Oncol. 1999;70:145-149.  [PubMed]  [DOI]
4.  Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R, Glaspy JA, McBride WH, Economou JS. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther. 1997;8:2173-2182.  [PubMed]  [DOI]
5.  Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.  [PubMed]  [DOI]
6.  Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002;35:S109-S114.  [PubMed]  [DOI]
7.  Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S319-S328.  [PubMed]  [DOI]
8.  Raper SE, Wilson JM. Gene therapy for human liver disease. Prog Liver Dis. 1995;13:201-230.  [PubMed]  [DOI]
9.  Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 2003;10:1241-1247.  [PubMed]  [DOI]
10.  Sato Y, Tanaka K, Lee G, Kanegae Y, Sakai Y, Kaneko S, Nakabayashi H, Tamaoki T, Saito I. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun. 1998;244:455-462.  [PubMed]  [DOI]
11.  Igarashi T, Suzuki S, Takahashi M, Tamaoki T, Shimada T. A novel strategy of cell targeting based on tissue-specific expression of the ecotropic retrovirus receptor gene. Hum Gene Ther. 1998;9:2691-2698.  [PubMed]  [DOI]
12.  Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res. 1997;9:313-325.  [PubMed]  [DOI]
13.  Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.  [PubMed]  [DOI]
14.  Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology. 1996;24:1264-1268.  [PubMed]  [DOI]
15.  Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther. 2002;9:346-355.  [PubMed]  [DOI]
16.  Vollmer CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999;59:3064-3067.  [PubMed]  [DOI]
17.  Wang XW, Xu B. Several new targets of antitumor agents. Zhongguo Yaoli Xuebao. 1997;18:289-292.  [PubMed]  [DOI]
18.  Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14 Suppl:S32-S36.  [PubMed]  [DOI]
19.  Chen XP, Zhao H, Zhao XP. Alternation of AFP-mRNA level detected in blood circulation during liver resection for HCC and its significance. World J Gastroenterol. 2002;8:818-821.  [PubMed]  [DOI]
20.  Lu SY, Sui YF, Li ZS, Pan CE, Ye J, Wang WY. Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma. World J Gastroenterol. 2003;9:688-691.  [PubMed]  [DOI]
21.  Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;2:191-197.  [PubMed]  [DOI]
22.  Barajas M, Mazzolini G, Genové G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology. 2001;33:52-61.  [PubMed]  [DOI]
23.  Ferry N. [Gene therapy of primary cancers of the liver: hopes and realities]. Bull Cancer. 1997;84:431-434.  [PubMed]  [DOI]
24.  Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.  [PubMed]  [DOI]
25.  Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, Shiratori Y, Hamada H, Omata M. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun. 2001;282:529-535.  [PubMed]  [DOI]
26.  Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol. 1991;11:5885-5893.  [PubMed]  [DOI]
27.  Kaneko S, Tamaoki T. Gene therapy vectors harboring AFP regulatory sequences. Preparation of an adenoviral vector. Mol Biotechnol. 2001;19:323-330.  [PubMed]  [DOI]
28.  Tamaoki T. Human alpha-fetoprotein transcriptional regulatory sequences. Application to gene therapy. Adv Exp Med Biol. 2000;465:47-56.  [PubMed]  [DOI]
29.  Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 1995;55:3105-3109.  [PubMed]  [DOI]
30.  Bilbao R, Gérolami R, Bralet MP, Qian C, Tran PL, Tennant B, Prieto J, Bréchot C. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther. 2000;7:657-662.  [PubMed]  [DOI]
31.  Ohguchi S, Nakatsukasa H, Higashi T, Ashida K, Nouso K, Ishizaki M, Hino N, Kobayashi Y, Uematsu S, Tsuji T. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology. 1998;27:599-607.  [PubMed]  [DOI]
32.  Cao G, Kuriyama S, Tsujinoue H, Chen Q, Mitoro A, Qi Z. A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. Int J Cancer. 2000;87:247-252.  [PubMed]  [DOI]
33.  Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, Hori T, Hirono S, Hayashi K, Tamaoki T. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 2001;61:3016-3021.  [PubMed]  [DOI]
34.  Ishikawa H, Nakata K, Mawatari F, Ueki T, Tsuruta S, Ido A, Nakao K, Kato Y, Ishii N, Eguchi K. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 1999;6:465-470.  [PubMed]  [DOI]
35.  Cao G, Kuriyama S, Gao J, Nakatani T, Chen Q, Yoshiji H, Zhao L, Kojima H, Dong Y, Fukui H. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer. 2001;37:140-147.  [PubMed]  [DOI]